Literature DB >> 10740978

Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.

S Begum1, T Sano, H Endo, H Kawamata, Y Urakami.   

Abstract

Low-grade mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach has been demonstrated to be closely linked to Helicobacter pylori (H. pylori) and to be frequently remissioned after the cure of H. pylori infection. Several previous studies have focused on proliferating lymphocytes but little is known about gastric epithelial change and the duration of the remission after the cure of H. pylori infection. We performed a long-term follow-up investigation on the effects of anti-H. pylori treatment on MALT lymphoma and chronic gastritis at the histologic and molecular levels. Forty-eight patients with low-grade gastric MALT lymphoma and 28 chronic gastritis patients in whom H. pylori infection was eradicated were studied. After eradication, 43 MALT lymphoma patients showed complete histologic remission and continuous remission was observed during follow-up for up to 43 months (mean, 17.8 months). As for epithelial changes after eradication, "emptiness of lamina propria" was more pronounced in the mucosa with MALT lymphoma than that with chronic gastritis, and its severity in MALT lymphoma cases significantly decreased during the observation period whereas the glandular area increased. Cystic change of the fundic gland also occurred more frequently in MALT lymphoma cases than chronic gastritis cases. B-cell clonality before eradication analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) was detected in almost all MALT lymphoma cases (43 cases), but rare in chronic gastritis cases (6 cases). After eradication, in spite of histologic regression, 21 MALT lymphoma patients had a persistent monoclonal population during the follow-up period. B-cell monoclonality preceding the malignant transformation was noted in 4 cases. These observations indicate that 1) complete histologic remission of low-grade gastric MALT lymphomas seems stable even if a monoclonal B cell population is detectable in some cases, 2) there may be a stage of disease where monoclonal B cells are present but there is no histologic evidence of MALT lymphoma, and 3) regenerative change of the damaged glands may occur in histologic regressed MALT lymphoma cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10740978

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  5 in total

Review 1.  Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists.

Authors:  Chris M Bacon; Ming-Qing Du; Ahmet Dogan
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

2.  IgH PCR of zinc formalin-fixed, paraffin-embedded non-lymphomatous gastric samples produces artifactual "clonal" bands not observed in paired tissues unexposed to zinc formalin.

Authors:  Kim Ahrens; Raul Braylan; Nidal Almasri; Robin Foss; Lisa Rimsza
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

3.  Clinicopathologic study of mucosa-associated lymphoid tissue lymphoma in gastroscopic biopsy.

Authors:  Hong Cheng; Jun Wang; Chuan-Shan Zhang; Pei-Song Yan; Xiao-Hui Zhang; Pei-Zhen Hu; Fu-Cheng Ma
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

Review 4.  Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis.

Authors:  Angelo Zullo; Cesare Hassan; Alessandro Andriani; Francesca Cristofari; Chiara Bassanelli; Gian Paolo Spinelli; Silverio Tomao; Sergio Morini
Journal:  Med Oncol       Date:  2009-03-24       Impact factor: 3.064

Review 5.  The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer.

Authors:  Rossella Cianci; Laura Franza; Giovanni Schinzari; Ernesto Rossi; Gianluca Ianiro; Giampaolo Tortora; Antonio Gasbarrini; Giovanni Gambassi; Giovanni Cammarota
Journal:  Int J Mol Sci       Date:  2019-01-24       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.